What is Zurex Pharma?
Zurex Pharma is dedicated to creating patented formulations designed to address unmet medical needs and improve patient outcomes. Their flagship product, ZuraGard, is engineered to prevent Surgical Site Infections (SSIs) by offering a superior antiseptic solution for pre-, peri-, and post-operative care. ZuraGard's innovative applicator streamlines the application process, enabling one-handed use, reducing preparation time, and demonstrating enhanced microbial reduction with less skin irritation compared to conventional methods. The company's focus on patient safety and operational efficiency positions it as a key player for healthcare providers seeking to optimize surgical environments.
How much funding has Zurex Pharma raised?
Zurex Pharma has raised a total of $17.4M across 4 funding rounds:
Series A
$6.2M
Private Equity
$846K
Series B
$4.1M
Series C
$6.2M
Series A (2012): $6.2M with participation from Wisconsin Investment Partners, Baird Venture Partners, and Peak Ridge Capital
Private Equity (2013): $846K, investors not publicly disclosed
Series B (2014): $4.1M supported by Baird Capital, State of Wisconsin - Investment Board, and Peak Ridge Capital
Series C (2016): $6.2M, investors not publicly disclosed
Key Investors in Zurex Pharma
Wisconsin Investment Partners
Wisconsin Investment Partners is an angel investment group and business incubator focused on funding and supporting entrepreneurs. They aim to drive growth within the entrepreneurial ecosystem through investment and networking opportunities.
Baird Venture Partners
Baird Capital is a private equity and venture capital firm specializing in founder-led B2B tech and services companies. They provide operational support and expertise to foster growth through a partnership approach.
Peak Ridge Capital
Peak Ridge Capital Group is an alternative asset management firm offering multi-asset class private investment opportunities, particularly in agriculture, real estate, and energy markets, to a sophisticated investor base.
What's next for Zurex Pharma?
The substantial enterprise-level funding and recent strategic investment indicate Zurex Pharma is poised for significant scaling and market penetration. This capital infusion will likely fuel further research and development, expand manufacturing capabilities, and support broader commercialization efforts for ZuraGard. The company's trajectory suggests a move towards solidifying its market position and potentially exploring new therapeutic areas or product enhancements to further its mission of improving patient care and healthcare economics.
See full Zurex Pharma company page
